MX2021003779A - Anticuerpos dirigidos a la epn1. - Google Patents

Anticuerpos dirigidos a la epn1.

Info

Publication number
MX2021003779A
MX2021003779A MX2021003779A MX2021003779A MX2021003779A MX 2021003779 A MX2021003779 A MX 2021003779A MX 2021003779 A MX2021003779 A MX 2021003779A MX 2021003779 A MX2021003779 A MX 2021003779A MX 2021003779 A MX2021003779 A MX 2021003779A
Authority
MX
Mexico
Prior art keywords
epn1
antibodies targeting
epsin
ameliorating
treating
Prior art date
Application number
MX2021003779A
Other languages
English (en)
Inventor
Matthew K Robinson
Original Assignee
Immunome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunome Inc filed Critical Immunome Inc
Publication of MX2021003779A publication Critical patent/MX2021003779A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Como aquí se describe, son anticuerpos específicos para la epsina-1 (EPN1), un antígeno expresado en la superficie de varias células cancerosas. También se publican métodos para tratar, mejorar y diagnosticar varios tipos de cáncer, caracterizados por células 5 tumorales que expresan EPN1.
MX2021003779A 2018-10-02 2019-10-02 Anticuerpos dirigidos a la epn1. MX2021003779A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862740092P 2018-10-02 2018-10-02
PCT/US2019/054259 WO2020072618A1 (en) 2018-10-02 2019-10-02 Antibodies targeting epn1

Publications (1)

Publication Number Publication Date
MX2021003779A true MX2021003779A (es) 2021-09-21

Family

ID=70055083

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003779A MX2021003779A (es) 2018-10-02 2019-10-02 Anticuerpos dirigidos a la epn1.

Country Status (12)

Country Link
US (1) US20220002435A1 (es)
EP (1) EP3860652A4 (es)
JP (1) JP2022501062A (es)
KR (1) KR20210090172A (es)
CN (1) CN113194992A (es)
AU (1) AU2019353009A1 (es)
BR (1) BR112021006431A2 (es)
CA (1) CA3115149A1 (es)
IL (1) IL282030A (es)
MX (1) MX2021003779A (es)
SG (1) SG11202103411RA (es)
WO (1) WO2020072618A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5985597A (en) * 1993-05-26 1999-11-16 Merck Frosst Canada, Inc. DNA encoding prostaglandin receptor EP1
US6720180B2 (en) * 2001-02-15 2004-04-13 Board Of Regents, The University Of Texas System Wounded epithelium-specific transcript
EP1308459A3 (en) * 2001-11-05 2003-07-09 Research Association for Biotechnology Full-length cDNA sequences
JP2005537783A (ja) 2002-03-28 2005-12-15 ザ ジェネティクス カンパニー インコーポレイティド 成長調節タンパク質
AU2005319578A1 (en) * 2004-11-24 2006-06-29 Neopro Labs, Llc Methods and compositions for treating conditions
JP2009518320A (ja) * 2005-12-05 2009-05-07 シュムフォウエン アクティーゼルスカブ 抗オルトポックスウイルス組換えポリクローナル抗体
EP2242836B1 (en) 2008-01-28 2015-05-20 Thomas Jefferson University Method of making hybrid cells that express useful antibodies
EP2623122A1 (en) * 2012-02-06 2013-08-07 Medizinische Hochschule Hannover Coated devices and methods for coating
AU2019359877A1 (en) 2018-10-17 2021-05-20 Immunome, Inc. Exosome-targeting bispecific antibodies

Also Published As

Publication number Publication date
AU2019353009A1 (en) 2021-05-20
SG11202103411RA (en) 2021-04-29
IL282030A (en) 2021-05-31
WO2020072618A1 (en) 2020-04-09
JP2022501062A (ja) 2022-01-06
BR112021006431A2 (pt) 2021-07-27
CN113194992A (zh) 2021-07-30
CA3115149A1 (en) 2020-04-09
KR20210090172A (ko) 2021-07-19
EP3860652A1 (en) 2021-08-11
EP3860652A4 (en) 2022-06-08
US20220002435A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
PH12020551160A1 (en) Chimeric antigen receptors targeting cd70
MX2020010458A (es) Conjugados de camptotecina-peptido.
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
MX2022003930A (es) Conjugados de péptido de camptotecina.
WO2018226685A3 (en) METHODS FOR THE SENSITIZATION OF CANCER CELLS TO MEDIATED DESTRUCTION BY T-LYMPHOCYTES BY MOLECULAR PATHWAY MODULATION
WO2016160618A3 (en) Car t-cell therapy directed to lhr for the treatment of solid tumors
MX2022002138A (es) Estandares de antigeno prostatico y sus usos.
ZA201907225B (en) Treatment of her2 positive cancers
ZA202110780B (en) Muc16 specific chimeric antigen receptors and uses thereof
MX2022003212A (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecificos anti-klk5/klk7 y metodos de uso.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX2020006171A (es) Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer.
JOP20220117A1 (ar) مستقبلات المستضدات الخيمرية المضادة لـ cd79 وخلايا car التائية واستخداماتهما
MX2020006131A (es) Linfocitos infiltrantes de medula especificos para cancer de prostata y usos de los mismos.
MX2020010104A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.
MX2022005816A (es) Terapia de tumores solidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70.
ZA202008095B (en) Humanized antibodies against psma
MX2023012681A (es) Receptores quimericos dirigidos a adgre2 y/o clec12a y usos de estos.
MX2021003262A (es) Metodos de tratamiento.
WO2019168897A3 (en) Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
SA521422250B1 (ar) أجسام مضادة للبيريوستين واستخداماتها
CR20220061A (es) Anticuerpos que se unen a células cancerosas y que dirigen radionucleidos a dichas células
PH12020552159A1 (en) Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use